|
Dr. Bossie received a B.S. degree in Biology from The College of New Jersey (formerly Trenton State), and earned his PhD in Microbiology and Molecular Biology at Rutgers University. Following his graduate studies, Dr. Mark Bossie joined the Molecular Biology Department at Princeton University, where he undertook and completed his post-doctoral research efforts.
Upon completion of his post-doctoral work, Dr. Bossie joined Bristol Myers-Squibb, developers of the world’s most widely used cancer treatment, Taxol®, a naturally-derived pharmaceutical compound.
Subsequently, Dr. Bossie accepted appointment as Senior Research Scientist at the Plant Biotechnology Department at American Cyanamid, and quickly rose to the rank of Group Leader, managing and leading research teams in various projects, including compound discovery.
Dr. Bossie was a central figure in the establishment of American Cyanamid’s most significant ventures into genomics-based discovery and initiatives into the use of plant biotechnology outside of crop protection.
Following the sale of American Cyanamid to BASF, Dr. Bossie accepted appointment as Research Director at Icon Genetics, a biotechnology company engaged in developing novel plant technologies targeted at the production of therapeutic pharmaceuticals in plant-based production systems.
Since the successful sale of Icon Genetics’ US interests, Dr. Mark A. Bossie has provided private consulting in the areas of biotechnology, and scientific and medical communications, working across a wide array of therapeutic disciplines for some of the world’s leading pharmaceutical companies. | 